Lixte Biotechnology Files 8-K on Agreements & Equity
Ticker: LIXT · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1335105
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
LIXTE BIOTECHNOLOGY FILES 8-K: MATERIAL AGREEMENTS, EQUITY SALES, AND FINANCIALS REPORTED.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on December 31, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial statements. The filing details events that occurred on December 30, 2025, with the company's principal executive offices located in Boca Raton, Florida.
Why It Matters
This 8-K filing signals significant corporate actions by Lixte Biotechnology, potentially impacting its financial structure and operational agreements.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered equity sales can indicate significant corporate changes or financing activities that carry inherent risks.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- December 30, 2025 (date) — Earliest event reported
- December 31, 2025 (date) — Filing date
- Boca Raton, Florida (location) — Principal executive offices
FAQ
What type of material definitive agreement was entered into by Lixte Biotechnology?
The filing indicates the entry into a material definitive agreement but does not specify the nature of the agreement in the provided text.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported was on December 30, 2025.
Where are Lixte Biotechnology's principal executive offices located?
The principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432.
What are the key items reported in this 8-K filing?
The key items reported are entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits.
What is the SEC file number for Lixte Biotechnology?
The SEC file number for Lixte Biotechnology is 001-39717.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-12-31 16:00:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
- $0.001 — 0 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 117KB
- 0001493152-25-029778.txt ( ) — 343KB
- lixt-20251230.xsd (EX-101.SCH) — 3KB
- lixt-20251230_lab.xml (EX-101.LAB) — 33KB
- lixt-20251230_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 31, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ Geordan Pursglove Geordan Pursglove Chairman of the Board and Chief Executive Officer